Read full article: CHEMOSAT and HEPZATO KIT are now included in ESMO–EURACAN clinical guidelines for uveal melanoma Recognized as key liver-directed therapies for metastatic uveal melanoma patients Supported by Phase 3 trial data showing improved progression-free survival and response rates NCCN continues to [...]
Read full article: The CHOPIN trial studied PHP combined with immunotherapy for metastatic uveal melanoma. PHP delivers high-dose melphalan directly to the liver to treat metastases. The trial enrolled 76 patients with liver-dominant disease. 1-year progression-free survival was 54.7% with the combination vs [...]
Read full article: The eyes can reveal early signs of ocular melanoma and other serious diseases. Comprehensive eye exams can detect diabetes, high blood pressure, and high cholesterol. Retinal blood vessels provide a unique view of vascular health. Diabetic retinopathy may appear years [...]
Read full article: The study analyzed 167 patients with conjunctival ocular melanoma over several decades. 25% of patients developed metastatic disease during long-term follow-up. Local recurrence occurred in 47% of patients, often preceding metastasis. Regional lymph node metastasis typically occurred before distant hematogenous [...]
Read full article: Five-year survival data marks a major milestone in ocular melanoma research Provides insight into long-term outcomes and treatment durability First approved therapy for metastatic ocular melanoma patients Uses innovative T-cell targeting immune technology May strengthen KIMMTRAK’s role in improving survival [...]
Read full article: The COOG2 study evaluated improved genetic testing strategies for uveal melanoma risk prediction. Combining DecisionDx-UM gene expression profiling with PRAME testing provides more accurate metastasis prediction. Traditional DNA mutation testing alone is less effective at predicting long-term outcomes. Improved risk [...]
Read full article: A Cure In Sight participated in the Melanoma Research Alliance Scientific Retreat in Washington, DC. The retreat is a premier gathering of global leaders in melanoma and ocular melanoma research. Scientists, clinicians, patient advocates, and industry leaders collaborate to advance [...]
Read full article: Phase 1 trial of PRAME-directed TCR therapy in metastatic uveal melanoma Overall response rate of 67%, unprecedented for this disease Durable responses with 71% overall survival at 12 months Demonstrated efficacy in patients with liver metastases Manageable safety profile with [...]
Read full article: Metastatic uveal melanoma historically had median OS under 6 months Advances in surveillance and liver-directed therapy have improved outcomes OptimUM-01 evaluated darovasertib plus crizotinib as first-line systemic therapy Median overall survival reported was 21.1 months Objective response rate reached 34.1%, [...]
Read full article: Subgroup analyses included 91 patients from the Phase 3 FOCUS study HEPZATO KIT showed consistent efficacy across most demographic and clinical subgroups Lower hepatic tumor burden was associated with significantly higher ORR and longer PFS Overall survival was significantly improved [...]
